Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia
To observe the treatment response of a two-dose regimen of inotuzumab ozogamicin (inotuzumab), a monoclonal antibody targeting CD22, for patients with heavily treated relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), including those failed or relapsed after chimeric antigen recept...
Gespeichert in:
| Veröffentlicht in: | Zhōnghuá xuèyèxué zázhì 2023-11, Vol.44 (11), p.911-916 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | chi |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 916 |
|---|---|
| container_issue | 11 |
| container_start_page | 911 |
| container_title | Zhōnghuá xuèyèxué zázhì |
| container_volume | 44 |
| creator | An, L L Zhao, D F Hou, R F Guan, H H Yan, H Lin, Y H Tong, C R Wu, T Liu, S Y |
| description | To observe the treatment response of a two-dose regimen of inotuzumab ozogamicin (inotuzumab), a monoclonal antibody targeting CD22, for patients with heavily treated relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), including those failed or relapsed after chimeric antigen receptor (CAR) -T-cell therapy.
Pediatric and adult patients who received two doses of inotuzumab and who were evaluated after inotuzumab treatment were included. Antibody infusions were performed between March 2020 and September 2022. All patients expressed CD22 antigen as detected by flow cytometry (>80% leukemic cells displaying CD22) before treatment. For adults, the maximum dosage per administration was 1 mg (with a total of two administrations). For children, the maximum dosage per administration was 0.85 mg/m(2) (no more than 1 mg/dose; total of two administrations). The total dosage administered to each patient was less than the standard dosage of 1.8 mg/m(2).
Twenty-one patients with R/R B-ALL were included, inc |
| doi_str_mv | 10.3760/cma.j.issn.0253-2727.2023.11.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2911845057</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2911845057</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-8b6b8830a3c65004db7a571c1c95aec255437baa4426fdf8a4f3ba4cbf894d133</originalsourceid><addsrcrecordid>eNo9kM1OwzAQhH0AQQW8AvKRS4J_4sQ9QsWfVIkLnKu1swFDHAfbESqPwFOTisJpNd_OrEZLyAVnpWxqdmk9lG-lS2komVCyEI1oSsGELDkvGVMHZPHPj8lZSs4wxWWtpWRH5FhqrpUSbEG-nyJC9jhkGjGNYUhIQ0eB5s9QtGFWEV_cvN_RnS6gfZtSxpa6IeTpa_JgaPgKL-CddcNM50QPY8L2MmIXweYQt_S6sNj3FOyUkfZbP74G00PKztIep3f0Dk7JYQd9wrP9PCHPtzdPq_ti_Xj3sLpaFyMXdS60qY3WkoG0tWKsak0DquGW26UCtEKpSjYGoKpE3bWdhqqTBiprOr2sWi7lCbn4vTvG8DFhyhvv0q4dDBimtBFLznWlmGpm6_neOhmP7WaMzkPcbv7-J38AAM55QA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2911845057</pqid></control><display><type>article</type><title>Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>An, L L ; Zhao, D F ; Hou, R F ; Guan, H H ; Yan, H ; Lin, Y H ; Tong, C R ; Wu, T ; Liu, S Y</creator><creatorcontrib>An, L L ; Zhao, D F ; Hou, R F ; Guan, H H ; Yan, H ; Lin, Y H ; Tong, C R ; Wu, T ; Liu, S Y</creatorcontrib><description>To observe the treatment response of a two-dose regimen of inotuzumab ozogamicin (inotuzumab), a monoclonal antibody targeting CD22, for patients with heavily treated relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), including those failed or relapsed after chimeric antigen receptor (CAR) -T-cell therapy.
Pediatric and adult patients who received two doses of inotuzumab and who were evaluated after inotuzumab treatment were included. Antibody infusions were performed between March 2020 and September 2022. All patients expressed CD22 antigen as detected by flow cytometry (>80% leukemic cells displaying CD22) before treatment. For adults, the maximum dosage per administration was 1 mg (with a total of two administrations). For children, the maximum dosage per administration was 0.85 mg/m(2) (no more than 1 mg/dose; total of two administrations). The total dosage administered to each patient was less than the standard dosage of 1.8 mg/m(2).
Twenty-one patients with R/R B-ALL were included, inc</description><identifier>ISSN: 0253-2727</identifier><identifier>DOI: 10.3760/cma.j.issn.0253-2727.2023.11.005</identifier><identifier>PMID: 38185520</identifier><language>chi</language><publisher>China</publisher><subject>Adaptor Proteins, Signal Transducing ; Adolescent ; Adult ; Antibodies, Monoclonal ; Antigens, CD19 ; Chemical and Drug Induced Liver Injury ; Child ; Humans ; Inotuzumab Ozogamicin ; Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy ; Receptors, Chimeric Antigen</subject><ispartof>Zhōnghuá xuèyèxué zázhì, 2023-11, Vol.44 (11), p.911-916</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38185520$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>An, L L</creatorcontrib><creatorcontrib>Zhao, D F</creatorcontrib><creatorcontrib>Hou, R F</creatorcontrib><creatorcontrib>Guan, H H</creatorcontrib><creatorcontrib>Yan, H</creatorcontrib><creatorcontrib>Lin, Y H</creatorcontrib><creatorcontrib>Tong, C R</creatorcontrib><creatorcontrib>Wu, T</creatorcontrib><creatorcontrib>Liu, S Y</creatorcontrib><title>Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia</title><title>Zhōnghuá xuèyèxué zázhì</title><addtitle>Zhonghua Xue Ye Xue Za Zhi</addtitle><description>To observe the treatment response of a two-dose regimen of inotuzumab ozogamicin (inotuzumab), a monoclonal antibody targeting CD22, for patients with heavily treated relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), including those failed or relapsed after chimeric antigen receptor (CAR) -T-cell therapy.
Pediatric and adult patients who received two doses of inotuzumab and who were evaluated after inotuzumab treatment were included. Antibody infusions were performed between March 2020 and September 2022. All patients expressed CD22 antigen as detected by flow cytometry (>80% leukemic cells displaying CD22) before treatment. For adults, the maximum dosage per administration was 1 mg (with a total of two administrations). For children, the maximum dosage per administration was 0.85 mg/m(2) (no more than 1 mg/dose; total of two administrations). The total dosage administered to each patient was less than the standard dosage of 1.8 mg/m(2).
Twenty-one patients with R/R B-ALL were included, inc</description><subject>Adaptor Proteins, Signal Transducing</subject><subject>Adolescent</subject><subject>Adult</subject><subject>Antibodies, Monoclonal</subject><subject>Antigens, CD19</subject><subject>Chemical and Drug Induced Liver Injury</subject><subject>Child</subject><subject>Humans</subject><subject>Inotuzumab Ozogamicin</subject><subject>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</subject><subject>Receptors, Chimeric Antigen</subject><issn>0253-2727</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kM1OwzAQhH0AQQW8AvKRS4J_4sQ9QsWfVIkLnKu1swFDHAfbESqPwFOTisJpNd_OrEZLyAVnpWxqdmk9lG-lS2komVCyEI1oSsGELDkvGVMHZPHPj8lZSs4wxWWtpWRH5FhqrpUSbEG-nyJC9jhkGjGNYUhIQ0eB5s9QtGFWEV_cvN_RnS6gfZtSxpa6IeTpa_JgaPgKL-CddcNM50QPY8L2MmIXweYQt_S6sNj3FOyUkfZbP74G00PKztIep3f0Dk7JYQd9wrP9PCHPtzdPq_ti_Xj3sLpaFyMXdS60qY3WkoG0tWKsak0DquGW26UCtEKpSjYGoKpE3bWdhqqTBiprOr2sWi7lCbn4vTvG8DFhyhvv0q4dDBimtBFLznWlmGpm6_neOhmP7WaMzkPcbv7-J38AAM55QA</recordid><startdate>20231114</startdate><enddate>20231114</enddate><creator>An, L L</creator><creator>Zhao, D F</creator><creator>Hou, R F</creator><creator>Guan, H H</creator><creator>Yan, H</creator><creator>Lin, Y H</creator><creator>Tong, C R</creator><creator>Wu, T</creator><creator>Liu, S Y</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20231114</creationdate><title>Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia</title><author>An, L L ; Zhao, D F ; Hou, R F ; Guan, H H ; Yan, H ; Lin, Y H ; Tong, C R ; Wu, T ; Liu, S Y</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-8b6b8830a3c65004db7a571c1c95aec255437baa4426fdf8a4f3ba4cbf894d133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>chi</language><creationdate>2023</creationdate><topic>Adaptor Proteins, Signal Transducing</topic><topic>Adolescent</topic><topic>Adult</topic><topic>Antibodies, Monoclonal</topic><topic>Antigens, CD19</topic><topic>Chemical and Drug Induced Liver Injury</topic><topic>Child</topic><topic>Humans</topic><topic>Inotuzumab Ozogamicin</topic><topic>Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy</topic><topic>Receptors, Chimeric Antigen</topic><toplevel>online_resources</toplevel><creatorcontrib>An, L L</creatorcontrib><creatorcontrib>Zhao, D F</creatorcontrib><creatorcontrib>Hou, R F</creatorcontrib><creatorcontrib>Guan, H H</creatorcontrib><creatorcontrib>Yan, H</creatorcontrib><creatorcontrib>Lin, Y H</creatorcontrib><creatorcontrib>Tong, C R</creatorcontrib><creatorcontrib>Wu, T</creatorcontrib><creatorcontrib>Liu, S Y</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Zhōnghuá xuèyèxué zázhì</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>An, L L</au><au>Zhao, D F</au><au>Hou, R F</au><au>Guan, H H</au><au>Yan, H</au><au>Lin, Y H</au><au>Tong, C R</au><au>Wu, T</au><au>Liu, S Y</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia</atitle><jtitle>Zhōnghuá xuèyèxué zázhì</jtitle><addtitle>Zhonghua Xue Ye Xue Za Zhi</addtitle><date>2023-11-14</date><risdate>2023</risdate><volume>44</volume><issue>11</issue><spage>911</spage><epage>916</epage><pages>911-916</pages><issn>0253-2727</issn><abstract>To observe the treatment response of a two-dose regimen of inotuzumab ozogamicin (inotuzumab), a monoclonal antibody targeting CD22, for patients with heavily treated relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), including those failed or relapsed after chimeric antigen receptor (CAR) -T-cell therapy.
Pediatric and adult patients who received two doses of inotuzumab and who were evaluated after inotuzumab treatment were included. Antibody infusions were performed between March 2020 and September 2022. All patients expressed CD22 antigen as detected by flow cytometry (>80% leukemic cells displaying CD22) before treatment. For adults, the maximum dosage per administration was 1 mg (with a total of two administrations). For children, the maximum dosage per administration was 0.85 mg/m(2) (no more than 1 mg/dose; total of two administrations). The total dosage administered to each patient was less than the standard dosage of 1.8 mg/m(2).
Twenty-one patients with R/R B-ALL were included, inc</abstract><cop>China</cop><pmid>38185520</pmid><doi>10.3760/cma.j.issn.0253-2727.2023.11.005</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0253-2727 |
| ispartof | Zhōnghuá xuèyèxué zázhì, 2023-11, Vol.44 (11), p.911-916 |
| issn | 0253-2727 |
| language | chi |
| recordid | cdi_proquest_miscellaneous_2911845057 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adaptor Proteins, Signal Transducing Adolescent Adult Antibodies, Monoclonal Antigens, CD19 Chemical and Drug Induced Liver Injury Child Humans Inotuzumab Ozogamicin Precursor Cell Lymphoblastic Leukemia-Lymphoma - therapy Receptors, Chimeric Antigen |
| title | Treatment response of a two-dose regimen of dose-adjusted inotuzumab ozogamicin in relapsed/refractory B-cell acute lymphoblastic leukemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T14%3A09%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20response%20of%20a%20two-dose%20regimen%20of%20dose-adjusted%20inotuzumab%20ozogamicin%20in%20relapsed/refractory%20B-cell%20acute%20lymphoblastic%20leukemia&rft.jtitle=Zh%C5%8Dnghu%C3%A1%20xu%C3%A8y%C3%A8xu%C3%A9%20z%C3%A1zh%C3%AC&rft.au=An,%20L%20L&rft.date=2023-11-14&rft.volume=44&rft.issue=11&rft.spage=911&rft.epage=916&rft.pages=911-916&rft.issn=0253-2727&rft_id=info:doi/10.3760/cma.j.issn.0253-2727.2023.11.005&rft_dat=%3Cproquest_pubme%3E2911845057%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2911845057&rft_id=info:pmid/38185520&rfr_iscdi=true |